信达生物(01801.HK)获摩根大通增持255.05万股
Ge Long Hui·2025-11-05 23:49

Group 1 - JPMorgan Chase & Co. increased its stake in Innovent Biologics (01801.HK) by acquiring 2.5505 million shares at an average price of HKD 80.6819 per share, totaling approximately HKD 206 million [1] - Following this acquisition, JPMorgan's total holdings in Innovent Biologics rose to 87,023,236 shares, increasing its ownership percentage from 4.92% to 5.07% [1]